Current progress and Perspectives of Research-Development in Bio-Technological Therapeutic Medicines
Modern biotechnology,closely related with the medical and pharmaceutical industry,has opened up a new dimension for therapeutic medicines. USA,Japan and the European Community are now the major countries involved in the research and develop ment of biotechnological medicines. There have been about 40 commercially available biotechnology medicines and vaccines,and approximately 400 products in the clinical trial stage starting from 1982(in which humulin was isolated)to September 1996. There are about 1,400 research and development institutes of biotechnological medicines,of which one- quarter has a real capacity in the world.In 1996,there were 113 such institutes in the United States. China began research in gene-engineering and molecular genetics in 1976.Since that time nearly 5,000 sci- entists have been engaged in the research and development of such bioteehn01ogical medicines.Currently there are 9 Ministry of Public Health-approved bioteehnology medicines and vaccines made by the clometic industry, available on market.For example,rhlFNα-2b and rh IL-2. It is predicted that 5 to 8 newly recombined protein medicines will become commercially available on interna- tional market each year for the next 5～6 years.Thus effective results will be achieved in the treatment of organ post-transplant rejection,acute attacks of autologous immune disease,septic shock,etc.